Response Genetics (RGDX) 0.44 $RGDX
Response Genetics reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 3:10PM CDT
RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Tue Mar 31, 3:05PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
RGDX: 0.44 (unch)
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 21.11 (-1.66), ARGS: 8.91 (-0.61), RXII: 0.72 (-0.02), CTSO: 13.19 (-0.68), ADK: 4.38 (+0.13), RGDX: 0.44 (unch), CLDN: 18.94 (-2.73)
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on March 31, 2015
GlobeNewswire - Thu Mar 19, 1:07PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2014 and give an operational update in a press release to be issued after the market closes on Tuesday, March 31, 2015. The company will host a conference call that same day at 4:30 p.m. Eastern time to discuss its financial results.
RGDX: 0.44 (unch)
Latest Updates in Healthcare Sector: Special Research on OncoGenex, Oxford Immunotec, Quidel, Response Genetics, and Trinity Biotech
PR Newswire - Tue Mar 10, 7:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OGXI: 2.15 (unch), RGDX: 0.44 (unch), QDEL: 26.98 (-0.52), TRIB: 19.25 (+0.06), OXFD: 14.08 (+0.81)
More nano cap med firms joining the bullish festivities
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 12:45PM CST
CYCC: 0.90 (-0.01), RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
RGDX: 0.44 (unch)
Update: Despite A Turnaround, Response Genetics Faces Nasdaq Delisting
Christopher F. Davis - at Seeking Alpha - Fri Dec 26, 10:44AM CST
RGDX: 0.44 (unch)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.44 (unch), AMRI: 17.60 (+0.05), VRML: 1.77 (-0.07)
Response Genetics Will See Record Revenues In 2015 On The Back Of New York State Approval
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 9:19AM CST
RGDX: 0.44 (unch)
Response Genetics Secures New York State Department of Health Approval for the Company's ResponseDX(R) Testing Services
GlobeNewswire - Thu Dec 11, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX sales in 2015.
RGDX: 0.44 (unch)
N-of-One Expands Executive Team to Meet Market Demand
Business Wire - Tue Dec 09, 12:00PM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced the appointment of two senior executives to support the company's rapid growth. The market for N-of-One's clinical interpretation is exploding, as evidenced by the significant number of new contracts N-of-One signed with major diagnostics companies and leading cancer centers in the past 12 months. In order to proactively support current and prospective clients' evolving needs in precision medicine, the company has created two new positions: Vice President of Sales and Vice President of Operations.
RGDX: 0.44 (unch)
Response Genetics Is Priced To Perish; Consider Before 2 Pending Catalysts
Christopher F. Davis - at Seeking Alpha - Sat Nov 29, 9:48AM CST
RGDX: 0.44 (unch)
Response Genetics' Quarter: I Think Retail Investors Are Overreacting And I'm Gladly Buying
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 11:54AM CST
RGDX: 0.44 (unch)
Response Genetics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:49AM CST
RGDX: 0.44 (unch)
Response Genetics' (RGDX) CEO Thomas Bologna on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:31AM CST
RGDX: 0.44 (unch)
Response Genetics EPS of -$0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:03AM CST
RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2014.
RGDX: 0.44 (unch)
Response Genetics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:38PM CST
RGDX: 0.44 (unch)
Response Genetics, Inc. to Release Third Quarter 2014 Financial Results and Host Conference Call on November 13, 2014
GlobeNewswire - Thu Nov 06, 12:03PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2014 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 13, 2014. The company will host a conference call that same day at 8:30 a.m. EST to discuss its financial results.
RGDX: 0.44 (unch)
Response Genetics reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 3:10PM CDT
RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Tue Mar 31, 3:05PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
RGDX: 0.44 (unch)
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 21.11 (-1.66), ARGS: 8.91 (-0.61), RXII: 0.72 (-0.02), CTSO: 13.19 (-0.68), ADK: 4.38 (+0.13), RGDX: 0.44 (unch), CLDN: 18.94 (-2.73)
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on March 31, 2015
GlobeNewswire - Thu Mar 19, 1:07PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2014 and give an operational update in a press release to be issued after the market closes on Tuesday, March 31, 2015. The company will host a conference call that same day at 4:30 p.m. Eastern time to discuss its financial results.
RGDX: 0.44 (unch)
Latest Updates in Healthcare Sector: Special Research on OncoGenex, Oxford Immunotec, Quidel, Response Genetics, and Trinity Biotech
PR Newswire - Tue Mar 10, 7:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OGXI: 2.15 (unch), RGDX: 0.44 (unch), QDEL: 26.98 (-0.52), TRIB: 19.25 (+0.06), OXFD: 14.08 (+0.81)
More nano cap med firms joining the bullish festivities
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 12:45PM CST
CYCC: 0.90 (-0.01), RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
RGDX: 0.44 (unch)
Update: Despite A Turnaround, Response Genetics Faces Nasdaq Delisting
Christopher F. Davis - at Seeking Alpha - Fri Dec 26, 10:44AM CST
RGDX: 0.44 (unch)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.44 (unch), AMRI: 17.60 (+0.05), VRML: 1.77 (-0.07)
Response Genetics Will See Record Revenues In 2015 On The Back Of New York State Approval
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 9:19AM CST
RGDX: 0.44 (unch)
Response Genetics Secures New York State Department of Health Approval for the Company's ResponseDX(R) Testing Services
GlobeNewswire - Thu Dec 11, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX sales in 2015.
RGDX: 0.44 (unch)
N-of-One Expands Executive Team to Meet Market Demand
Business Wire - Tue Dec 09, 12:00PM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced the appointment of two senior executives to support the company's rapid growth. The market for N-of-One's clinical interpretation is exploding, as evidenced by the significant number of new contracts N-of-One signed with major diagnostics companies and leading cancer centers in the past 12 months. In order to proactively support current and prospective clients' evolving needs in precision medicine, the company has created two new positions: Vice President of Sales and Vice President of Operations.
RGDX: 0.44 (unch)
Response Genetics Is Priced To Perish; Consider Before 2 Pending Catalysts
Christopher F. Davis - at Seeking Alpha - Sat Nov 29, 9:48AM CST
RGDX: 0.44 (unch)
Response Genetics' Quarter: I Think Retail Investors Are Overreacting And I'm Gladly Buying
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 11:54AM CST
RGDX: 0.44 (unch)
Response Genetics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:49AM CST
RGDX: 0.44 (unch)
Response Genetics' (RGDX) CEO Thomas Bologna on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:31AM CST
RGDX: 0.44 (unch)
Response Genetics EPS of -$0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:03AM CST
RGDX: 0.44 (unch)
Response Genetics, Inc. Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2014.
RGDX: 0.44 (unch)
Response Genetics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:38PM CST
RGDX: 0.44 (unch)
Response Genetics, Inc. to Release Third Quarter 2014 Financial Results and Host Conference Call on November 13, 2014
GlobeNewswire - Thu Nov 06, 12:03PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2014 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 13, 2014. The company will host a conference call that same day at 8:30 a.m. EST to discuss its financial results.
RGDX: 0.44 (unch)
